Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561779 | 0.88 | CYP2D6 (0.37) | ALDH1A1LMNAMAPK1MEN1POLB | |
| SCHEMBL7592044 | 0.87 | OPRD1 (0.37) | MEN1POLBKMT2A | |
| SCHEMBL6807252 | 0.85 | CCR4 (0.40) | MAPK1MEN1POLBKMT2A | |
| SCHEMBL7562558 | 0.78 | CYP2C19 (0.32) | ALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL7565573 | 0.74 | ALDH1A1 (0.31) | ALDH1A1LMNAMAPK1MEN1KMT2A | |
| SCHEMBL6911507 | 0.70 | — | — | |
| SCHEMBL7563873 | 0.68 | CDK1 (0.46) | — | |
| SCHEMBL31487941 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL7562562 | 0.67 | ALDH1A1 (0.40) | ALDH1A1LMNAMEN1POLBKMT2A | |
| SCHEMBL31488218 | 0.65 | FLT1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | ALDH1A1 267/4885LMNA 4566/4885MAPK1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.